FindTrial
Sign In

The protection of intestinal barrier function and reduction of inflammatory response by compound probiotics in patients with liver cirrhosis: a randomized, double-blind controlled study

The protection of intestinal barrier function and reduction of inflammatory response by compound probiotics in patients with liver cirrhosis: a randomized, double-blind controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054420
Enrollment
Unknown
Registered
2021-12-17
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cirrhosis

Interventions

Control group:conventional therapy
Experimental group:Compound probiotics plus routine treatment

Sponsors

Inner Mongolia People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Clinical, laboratory and imaging findings suggest abnormal liver function and / or portal hypertension, and / or histological manifestations of liver cirrhosis.

Exclusion criteria

Exclusion criteria: 1. Various types of infectious bowel disease; 2. Various types of functional bowel disease; 3. Inflammatory bowel disease; 4. Vascular enteropathy such as ischemic bowel disease and acute superior mesenteric artery embolism; 5. Intestinal malignant tumor; 6. Other primary enteropathy.

Design outcomes

Primary

MeasureTime frame
Clinical symptoms;Intestinal barrier function;Intestinal flora;Inflammatory factor;Metabonomics;—

Countries

China

Contacts

Public ContactWang Huan

Inner Mongolia People's Hospital

389523487@qq.com+86 15847676576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026